# China NMPA Drug Inspection - Jilin Xinhui Pharmaceutical Co., Ltd. - Traumatic Injury and Blood Circulation Powder

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/jilin-xinhui-pharmaceutical-co-ltd/66cff6e7-2046-423e-bd47-b3659ed516d7/
Source feed: China

> China NMPA drug inspection for Jilin Xinhui Pharmaceutical Co., Ltd. published August 09, 2016. Drug: Traumatic Injury and Blood Circulation Powder. In August 2016, the State Administration for Market Regulation (formerly China Food and Drug Administration) issued an a

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: State Administration of Drug Administration Announcement No. 117 of 2016 Regarding Multiple Batches of Substandard Drugs from Three Companies Including Hubei Ji'antang Pharmaceutical Co., Ltd.
- Company Name: Jilin Xinhui Pharmaceutical Co., Ltd.
- Publication Date: 2016-08-09
- Drug Name: Traumatic Injury and Blood Circulation Powder
- Inspection Finding: Multiple batches of medicines had unacceptable discrepancies in fill weight, reflecting problems in production quality management.
- Action Taken: Production and sales shall be suspended and products recalled; the matter shall be investigated and dealt with in accordance with the provisions of the "Drug Administration Law of the People's Republic of China"; the cause of the drug quality problem shall be thoroughly investigated and rectified, and production shall not be resumed until the rectification is completed.
- Summary: In August 2016, the State Administration for Market Regulation (formerly China Food and Drug Administration) issued an announcement regarding multiple batches of substandard drugs identified during national sampling inspections. Three pharmaceutical companies were implicated due to significant quality control deficiencies in their production processes. Hubei Ji'antang Pharmaceutical Co., Ltd. had four batches of its 'Snake Gallbladder and Fritillaria Liquid' identified as substandard concerning their identification properties. Jilin Xinhui Pharmaceutical Co., Ltd. was found to have three batches of 'Trauma and Blood Circulation Powder' failing content uniformity standards. Additionally, Sichuan Tongyuan Pharmaceutical Co., Ltd. had three batches of its 'Children's Cough and Asthma Relief Granules' deemed substandard based on their appearance. As a result of these findings, the provincial Food and Drug Administrations in Hubei, Jilin, and Sichuan were instructed to implement stringent measures. These included ordering the companies to immediately suspend production and sales, initiate product recalls, and face penalties in accordance with the 'Drug Administration Law of the People's Republic of China.' Furthermore, the companies are required to thoroughly investigate the root causes of these quality issues, implement comprehensive corrective actions, and are prohibited from resuming production until full rectification is confirmed. The regulatory bodies committed to publicly disclosing the progress of these actions.

Company: https://www.globalkeysolutions.net/companies/jilin-xinhui-pharmaceutical-co-ltd/0e864bd1-b082-4645-972a-2a593a5c9958/